Bio-Rad Reports Third-Quarter 2019 Financial Results
October 31, 2019HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019.
Third-quarter 2019 net sales were $560.6 million, an increase of 2.8 percent compared to $545.1 million reported for the third quarter of 2018. On a currency-neutral basis, quarterly sales increased 4.5 percent compared to the same period in 2018, reflecting growth across the business. Third-quarter gross margin was 54.8 percent compared to 52.6 percent during the third quarter in 2018.
Life Science segment net sales for the third quarter were $215.7 million, an increase of 4.5 percent compared to the same period in 2018. On a currency-neutral basis, Life Science segment sales increased by 5.7 percent compared to the same quarter in 2018. Currency-neutral sales reflect growth of multiple product lines in the segment, driven by double-digit growth in Droplet Digital PCR and Food Safety products as well as good demand within Gene Expression and Western Blotting product lines. Sales during the third quarter of 2019 increased across all regions: the Americas, Europe and Asia.
Clinical Diagnostics segment net sales for the third quarter were $341.8 million, an increase of 2.4 percent compared to the same period in 2018. On a currency-neutral basis, net sales were up 4.3 percent compared to the same quarter last year. Currency-neutral sales from the third quarter reflected growth in Quality Control, Blood Typing, and Immunology product lines. On a geographic view, sales increased mainly in Asia and the Americas.
Third-quarter 2019 operating income was $57.5 million versus 2018 third-quarter operating income of $36.3 million.
Reported net income for the third quarter of 2019 was a net loss of $258.8 million, or ($8.68) per share on a diluted basis. This loss was negatively impacted by a decline of $390.6 million in the market value of equity securities that we hold, primarily related to our investment in Sartorius AG. Net income for the third quarter of 2018 was a net gain of $269.3 million, or $8.89 per share on a diluted basis, which included a gain of $318.0 million related to our investment holdings.
The effective tax rate for the third quarter of 2019 was 22.8 percent compared to 23.1 percent during the same quarter in 2018.
“We are pleased with our operating results for the third quarter, which show continued strength in many of our key life science and diagnostic product lines across most of our major geographies,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “Our operating performance reflects continued improvement compared to 2018, providing us with good momentum as we head into the rest of the year.”
|
GAAP Results |
||||||
|
|
Q3 2019 |
Q3 2018 |
||||
|
Revenue (Millions) |
$560.6 |
$545.1 |
||||
|
Gross Margin |
54.8% |
52.6% |
||||
|
Operating Margin |
10.2% |
6.7% |
||||
|
Net (Loss) Income (Millions) |
($258.8) |
$269.3 |
||||
|
(Loss) Income per Diluted Share |
($8.68) |
$8.89 |
||||
|
|
||||||
|
Non-GAAP Results |
||||||
|
|
Q3 2019 |
Q3 2018 |
||||
|
Gross Margin |
56.0% |
53.5% |
||||
|
Operating Margin |
12.0% |
8.2% |
||||
|
Net Income (Millions) |
$48.6 |
$27.6 |
||||
|
Income per Diluted Share |
$1.61 |
$0.91 |
||||
A reconciliation between GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release. Non-GAAP adjustments include amortization of purchased intangibles; acquisition-related expenses and benefits; restructuring, impairment charges and valuation changes in equity owned investments; gains and losses on equity-method investments; significant litigation charges or benefits and legal costs; and discrete income tax events and the income tax effect on these non-GAAP adjustments.
Non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS) are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Non-GAAP Reporting.”
Non-GAAP net income for the third quarter of 2019 was $48.6 million, or $1.61 per share on a diluted basis, compared to $27.6 million, or $0.91 per share on a diluted basis, during the same period in 2018. The non-GAAP effective tax rate for the third quarter of 2019 was 25.5 percent compared to 31.9 percent for the same period in 2018.
The following table represents a reconciliation of Bio-Rad’s reported net (loss) income and diluted (loss) income per share to non-GAAP net income and non-GAAP diluted income per share for the three and nine months ended September 30, 2019 and 2018:
|
|
Three Months Ended |
Nine Months Ended |
|||||||||||
|
(in thousands, except per share data) |
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||
|
GAAP net (loss) income |
$(258,816) |
|
$269,326 |
|
$1,205,189 |
|
$1,194,143 |
||||||
|
Amortization of purchased intangibles |
5,809 |
|
6,529 |
|
16,490 |
|
20,179 |
||||||
|
Legal matters |
(1,900) |
|
4,420 |
|
4,593 |
|
13,209 |
||||||
|
Acquisition-related costs (benefits) |
6 |
|
(2,756) |
|
(7,762) |
|
(2,862) |
||||||
|
Restructuring costs (benefits) |
5,928 |
|
(10) |
|
5,749 |
|
1,478 |
||||||
|
Valuation loss (gain) on equity-owned securities |
390,620 |
|
(318,007) |
|
(1,384,999) |
|
(1,420,339) |
||||||
|
Loss on equity-method investments |
37 |
|
222 |
|
698 |
|
625 |
||||||
|
Other non-recurring items |
– |
|
– |
|
(759) |
|
(9,208) |
||||||
|
Income tax effect on non-GAAP adjustments |
(93,040) |
|
67,878 |
|
303,890 |
|
315,276 |
||||||
|
Non-GAAP net income |
$48,644 |
|
$27,602 |
|
$143,089 |
|
$112,501 |
||||||
|
|
|
|
|
|
|
|
|
||||||
|
GAAP diluted (loss) income per share |
$(8.68) |
|
$8.89 |
|
$39.97 |
|
$39.50 |
||||||
|
Non-GAAP diluted income per share |
$1.61 |
|
$0.91 |
|
$4.75 |
|
$3.72 |
||||||
On a reported basis, net sales for the first three quarters of 2019 increased 0.9 percent to $1,687.2 million compared to $1,672.6 million for the same period in 2018. On a currency-neutral basis, net sales grew 3.7 percent.
Year-to-date net income for 2019 was $1,205.2 million, or $39.97 per share on a fully diluted basis, compared to $1,194.1 million, or $39.50 per share, respectively, during the same period in 2018.
2019 Financial Outlook
For the full year 2019, the company is projecting currency-neutral revenue growth outlook of 4.0 to 4.5 percent with an estimated non-GAAP operating margin of 12.5 to 13.0 percent.
“As we head into the end of the year, we anticipate 2019 will be another year of growth in many of our key product areas, with broad contribution from most of our major geographies,” Mr. Schwartz said. “Our operating performance has rebounded nicely so far in 2019 and we expect more of the same for the remainder of the year, reflecting substantial improvement in operating profit over 2018.”
Non-GAAP Reporting
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, valuation changes of equity owned investments, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:
Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.
Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, valuation costs, integration costs, changes in the fair value of contingent consideration liabilities, gain or expense on settlement of pre-existing relationships, and other professional or consulting fees. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.
Restructuring, impairment charges, valuation changes in equity owned investments and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets, charges and benefits arising from valuation changes in equity owned investments and gains and losses on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.
Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.
Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.
From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.
There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.
The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Conference Call and Webcast
Management will discuss third quarter ended September 30, 2019 results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) October 31, 2019. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., Conference ID: 1469320. You may also listen to the conference call via a webcast that is available in the “Investor Relations” section of our website under “Quarterly Results” at www.bio-rad.com. The webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results, our operating results for the third quarter showing continued strength in many of our key life science and diagnostic product lines across most of our major geographies, our operating performance reflecting continued improvement compared to 2018, providing us with good momentum as we head into the rest of the year, anticipating 2019 will be another year of growth in many of our key product areas with broad contribution from most of our major geographies, expecting our operating performance to continue to rebound for the remainder of the year which will reflect substantial improvement in operating profit over 2018, and for the full year 2019 projecting currency-neutral revenue growth outlook of 4.0 to 4.5 percent with an estimated non-GAAP operating margin of 12.5 to 13.0 percent.. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “anticipate,” “expect,” “project,” “continue,” “estimate,” “believe,” “will,” “assume,” “may,” “intend,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, international legal and regulatory risks, global economic and geopolitical conditions, product quality and liability issues, reductions in government funding or capital spending of our customers, our ability to integrate acquired companies, products or technologies into our company successfully, supply chain issues, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s public reports filed with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2019 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.
| Bio-Rad Laboratories, Inc. | |||||||||||||||||||
| Condensed Consolidated Statements of Income | |||||||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||||
| (Unaudited) | |||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||||||
| Net sales |
$ |
560,633 |
|
$ |
545,138 |
|
$ |
1,687,231 |
|
$ |
1,672,568 |
|
|||||||
| Cost of goods sold |
|
253,607 |
|
|
258,422 |
|
|
760,674 |
|
|
781,982 |
|
|||||||
| Gross profit |
|
307,026 |
|
|
286,716 |
|
|
926,557 |
|
|
890,586 |
|
|||||||
| Selling, general and administrative expense |
|
201,622 |
|
|
201,196 |
|
|
610,460 |
|
|
620,751 |
|
|||||||
| Research and development expense |
|
47,944 |
|
|
49,245 |
|
|
145,641 |
|
|
146,122 |
|
|||||||
| Income from operations |
|
57,460 |
|
|
36,275 |
|
|
170,456 |
|
|
123,713 |
|
|||||||
| Interest expense |
|
5,525 |
|
|
6,064 |
|
|
17,352 |
|
|
17,823 |
|
|||||||
| Foreign currency exchange losses, net |
|
898 |
|
|
672 |
|
|
3,411 |
|
|
1,911 |
|
|||||||
| Change in fair market value of equity securities |
|
390,620 |
|
|
(318,007 |
) |
|
(1,384,999 |
) |
|
(1,420,339 |
) |
|||||||
| Other (income) expense, net |
|
(4,367 |
) |
|
(2,585 |
) |
|
(26,959 |
) |
|
(29,588 |
) |
|||||||
| (Loss) income before income taxes |
|
(335,216 |
) |
|
350,131 |
|
|
1,561,651 |
|
|
1,553,906 |
|
|||||||
| Benefit from (provision for) income taxes |
|
76,400 |
|
|
(80,805 |
) |
|
(356,462 |
) |
|
(359,763 |
) |
|||||||
| Net (loss) income |
$ |
(258,816 |
) |
$ |
269,326 |
|
$ |
1,205,189 |
|
$ |
1,194,143 |
|
|||||||
| Basic (loss) earnings per share: | |||||||||||||||||||
| Net (loss) income per basic share |
$ |
(8.68 |
) |
$ |
9.02 |
|
$ |
40.42 |
|
$ |
40.04 |
|
|||||||
| Weighted average common shares – basic |
|
29,831 |
|
|
29,863 |
|
|
29,815 |
|
|
29,822 |
|
|||||||
| Diluted (loss) earnings per share: | |||||||||||||||||||
| Net (loss) income per diluted share |
$ |
(8.68 |
) |
$ |
8.89 |
|
$ |
39.97 |
|
$ |
39.50 |
|
|||||||
| Weighted average common shares – diluted |
|
29,831 |
|
|
30,292 |
|
|
30,149 |
|
|
30,234 |
|
|||||||
|
Note: |
As a result of the net loss for the three months ended September 30, 2019, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive. | ||||||
| Bio-Rad Laboratories, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (In thousands) | |||||||
| September 30, | December 31, | ||||||
|
2019 |
2018 |
||||||
| (Unaudited) | |||||||
| Current assets: | |||||||
| Cash and cash equivalents |
$ |
561,071 |
$ |
431,526 |
|||
| Short-term investments |
|
423,737 |
|
418,830 |
|||
| Accounts receivable, net |
|
356,025 |
|
392,443 |
|||
| Inventories, net |
|
587,987 |
|
583,815 |
|||
| Other current assets |
|
118,812 |
|
196,864 |
|||
| Total current assets |
|
2,047,632 |
|
2,023,478 |
|||
| Property, plant and equipment, net |
|
495,876 |
|
508,690 |
|||
| Operating lease right-of-use assets |
|
217,516 |
|
– |
|||
| Goodwill, net |
|
264,084 |
|
219,770 |
|||
| Purchased intangibles, net |
|
146,965 |
|
133,123 |
|||
| Other investments |
|
3,931,715 |
|
2,655,709 |
|||
| Other assets |
|
73,328 |
|
70,298 |
|||
| Total assets |
$ |
7,177,116 |
$ |
5,611,068 |
|||
| Current liabilities: | |||||||
| Accounts payable, accrued payroll and employee benefits |
$ |
249,835 |
$ |
265,960 |
|||
| Current maturities of long-term debt |
|
1,769 |
|
493 |
|||
| Income and other taxes payable |
|
35,252 |
|
56,188 |
|||
| Other current liabilities |
|
147,184 |
|
128,154 |
|||
| Total current liabilities |
|
434,040 |
|
450,795 |
|||
| Long-term debt, net of current maturities |
|
437,808 |
|
438,937 |
|||
| Other long-term liabilities |
|
1,174,076 |
|
701,005 |
|||
| Total liabilities |
|
2,045,924 |
|
1,590,737 |
|||
| Total stockholders’ equity |
|
5,131,192 |
|
4,020,331 |
|||
| Total liabilities and stockholders’ equity |
$ |
7,177,116 |
$ |
5,611,068 |
|||
| Bio-Rad Laboratories, Inc. | ||||
| Condensed Consolidated Statements of Cash Flows | ||||
| (In thousands) | ||||
| (Unaudited) | ||||
| Nine Months Ended | ||||
| September 30, | ||||
|
2019 |
2018 |
|||
| Cash flows from operating activities: | ||||
| Cash received from customers |
$ 1,716,486 |
$ 1,715,960 |
||
| Cash paid to suppliers and employees |
(1,392,653) |
(1,494,794) |
||
| Interest paid, net |
(11,381) |
(11,721) |
||
| Income tax payments, net |
(42,634) |
(57,840) |
||
| Other operating activities |
28,277 |
28,880 |
||
| Net cash provided by operating activities |
298,095 |
180,485 |
||
| Cash flows from investing activities: | ||||
| (Payments for) proceeds from acquisitions |
(75,811) |
266 |
||
| Other investing activities |
(71,882) |
(132,433) |
||
| Net cash used in investing activities |
(147,693) |
(132,167) |
||
| Cash flows from financing activities: | ||||
| Payments on long-term borrowings |
(487) |
(1,595) |
||
| Other financing activities |
(17,488) |
(82) |
||
| Net cash used in financing activities |
(17,975) |
(1,677) |
||
| Effect of foreign exchange rate changes on cash |
(3,239) |
3,965 |
||
| Net increase in cash, cash equivalents, and restricted cash |
129,188 |
50,606 |
||
| Cash, cash equivalents, and restricted cash at beginning of period |
434,164 |
384,983 |
||
| Cash, cash equivalents, and restricted cash at end of period |
$ 563,352 |
$ 435,589 |
||
| Reconciliation of net income to net cash provided by operating activities: | ||||
| Net income |
$ 1,205,189 |
$ 1,194,143 |
||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization |
99,757 |
103,509 |
||
| Right-of-use asset amortization |
31,108 |
– |
||
| Changes in working capital |
8,861 |
(28,087) |
||
| Other |
(1,046,820) |
(1,089,080) |
||
| Net cash provided by operating activities |
$ 298,095 |
$ 180,485 |
||
Bio-Rad Laboratories, Inc.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In thousands, except per share data)
(Unaudited)
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; valuation changes of equity owned investments; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.
| Three Months Ended |
Three Months Ended |
Nine Months Ended |
Nine Months Ended |
|||||||||||||||||||||||||||||||||
| September 30, | % of | September 30, | % of | September 30, | % of | September 30, | % of | |||||||||||||||||||||||||||||
|
2019 |
revenue |
2018 |
revenue |
2019 |
revenue |
2018 |
revenue | |||||||||||||||||||||||||||||
| GAAP cost of goods sold |
$ |
253,607 |
|
$ |
258,422 |
|
$ |
760,674 |
|
$ |
781,982 |
|
||||||||||||||||||||||||
| Amortization of purchased intangibles |
|
(3,944 |
) |
|
(4,726 |
) |
|
(11,366 |
) |
|
(14,252 |
) |
||||||||||||||||||||||||
| Acquisition related benefits (costs) (1) |
|
– |
|
|
– |
|
|
7,403 |
|
|
– |
|
||||||||||||||||||||||||
| Restructuring benefits (costs) |
|
(3,243 |
) |
|
(410 |
) |
|
(3,051 |
) |
|
(1,884 |
) |
||||||||||||||||||||||||
| Non-GAAP cost of goods sold |
$ |
246,420 |
|
$ |
253,286 |
|
$ |
753,660 |
|
$ |
765,846 |
|
||||||||||||||||||||||||
| GAAP gross profit |
$ |
307,026 |
|
54.8 |
% |
$ |
286,716 |
|
52.6 |
% |
$ |
926,557 |
|
54.9 |
% |
$ |
890,586 |
|
53.2 |
% |
||||||||||||||||
| Amortization of purchased intangibles |
|
3,944 |
|
|
4,726 |
|
|
11,366 |
|
|
14,252 |
|
||||||||||||||||||||||||
| Acquisition related (benefits) costs (1) |
|
– |
|
|
– |
|
|
(7,403 |
) |
|
– |
|
||||||||||||||||||||||||
| Restructuring (benefits) costs |
|
3,243 |
|
|
410 |
|
|
3,051 |
|
|
1,884 |
|
||||||||||||||||||||||||
| Non-GAAP gross profit |
$ |
314,213 |
|
56.0 |
% |
$ |
291,852 |
|
53.5 |
% |
$ |
933,571 |
|
55.3 |
% |
$ |
906,722 |
|
54.2 |
% |
||||||||||||||||
| GAAP selling, general and administrative expense |
$ |
201,622 |
|
$ |
201,196 |
|
$ |
610,460 |
|
$ |
620,751 |
|
||||||||||||||||||||||||
| Amortization of purchased intangibles |
|
(1,865 |
) |
|
(1,803 |
) |
|
(5,124 |
) |
|
(5,927 |
) |
||||||||||||||||||||||||
| Legal matters |
|
1,900 |
|
|
(4,420 |
) |
|
(4,593 |
) |
|
(13,209 |
) |
||||||||||||||||||||||||
| Acquisition related benefits (costs) (1) |
|
(6 |
) |
|
2,756 |
|
|
359 |
|
|
3,374 |
|
||||||||||||||||||||||||
| Restructuring benefits (costs) |
|
(2,662 |
) |
|
(76 |
) |
|
(2,802 |
) |
|
(434 |
) |
||||||||||||||||||||||||
| Non-GAAP selling, general and administrative expense |
$ |
198,989 |
|
$ |
197,653 |
|
$ |
598,300 |
|
$ |
604,555 |
|
||||||||||||||||||||||||
| GAAP research and development expense |
$ |
47,944 |
|
$ |
49,245 |
|
$ |
145,641 |
|
$ |
146,122 |
|
||||||||||||||||||||||||
| Acquisition related benefits (costs) (1) |
|
– |
|
|
– |
|
|
– |
|
|
(512 |
) |
||||||||||||||||||||||||
| Restructuring benefits (costs) |
|
(23 |
) |
|
496 |
|
|
104 |
|
|
840 |
|
||||||||||||||||||||||||
| Non-GAAP research and development expense |
$ |
47,921 |
|
$ |
49,741 |
|
$ |
145,745 |
|
$ |
146,450 |
|
||||||||||||||||||||||||
| GAAP income from operations |
$ |
57,460 |
|
10.2 |
% |
$ |
36,275 |
|
6.7 |
% |
$ |
170,456 |
|
10.1 |
% |
$ |
123,713 |
|
7.4 |
% |
||||||||||||||||
| Amortization of purchased intangibles |
|
5,809 |
|
|
6,529 |
|
|
16,490 |
|
|
20,179 |
|
||||||||||||||||||||||||
| Legal matters |
|
(1,900 |
) |
|
4,420 |
|
|
4,593 |
|
|
13,209 |
|
||||||||||||||||||||||||
| Acquisition related (benefits) costs (1) |
|
6 |
|
|
(2,756 |
) |
|
(7,762 |
) |
|
(2,862 |
) |
||||||||||||||||||||||||
| Restructuring (benefits) costs |
|
5,928 |
|
|
(10 |
) |
|
5,749 |
|
|
1,478 |
|
||||||||||||||||||||||||
| Non-GAAP income from operations |
$ |
67,303 |
|
12.0 |
% |
$ |
44,458 |
|
8.2 |
% |
$ |
189,526 |
|
11.2 |
% |
$ |
155,717 |
|
9.3 |
% |
||||||||||||||||
| GAAP change in fair market value of equity securities |
$ |
390,620 |
|
$ |
(318,007 |
) |
$ |
(1,384,999 |
) |
$ |
(1,420,339 |
) |
||||||||||||||||||||||||
| Valuation (loss) gain on equity-owned securities |
|
(390,620 |
) |
|
318,007 |
|
|
1,384,999 |
|
|
1,420,339 |
|
||||||||||||||||||||||||
| Non-GAAP change in fair market value of equity securities |
$ |
– |
|
$ |
– |
|
$ |
– |
|
$ |
– |
|
||||||||||||||||||||||||
| GAAP other (income) expense, net |
$ |
(4,367 |
) |
$ |
(2,585 |
) |
$ |
(26,959 |
) |
$ |
(29,588 |
) |
||||||||||||||||||||||||
| (Loss) gain on equity-method investments |
|
(37 |
) |
|
(222 |
) |
|
(698 |
) |
|
(625 |
) |
||||||||||||||||||||||||
| Other non-recurring items (2) |
|
– |
|
|
– |
|
|
759 |
|
|
9,208 |
|
||||||||||||||||||||||||
| Non-GAAP other (income) expense, net |
$ |
(4,404 |
) |
$ |
(2,807 |
) |
$ |
(26,898 |
) |
$ |
(21,005 |
) |
||||||||||||||||||||||||
| GAAP (loss) income before income taxes |
$ |
(335,216 |
) |
$ |
350,131 |
|
$ |
1,561,651 |
|
$ |
1,553,906 |
|
||||||||||||||||||||||||
| Amortization of purchased intangibles |
|
5,809 |
|
|
6,529 |
|
|
16,490 |
|
|
20,179 |
|
||||||||||||||||||||||||
| Legal matters |
|
(1,900 |
) |
|
4,420 |
|
|
4,593 |
|
|
13,209 |
|
||||||||||||||||||||||||
| Acquisition related (benefits) costs (1) |
|
6 |
|
|
(2,756 |
) |
|
(7,762 |
) |
|
(2,862 |
) |
||||||||||||||||||||||||
| Restructuring (benefits) costs |
|
5,928 |
|
|
(10 |
) |
|
5,749 |
|
|
1,478 |
|
||||||||||||||||||||||||
| Valuation loss (gain) on equity-owned securities |
|
390,620 |
|
|
(318,007 |
) |
|
(1,384,999 |
) |
|
(1,420,339 |
) |
||||||||||||||||||||||||
| Loss (gain) on equity-method investments |
|
37 |
|
|
222 |
|
|
698 |
|
|
625 |
|
||||||||||||||||||||||||
| Other non-recurring items (2) |
|
– |
|
|
– |
|
|
(759 |
) |
|
(9,208 |
) |
||||||||||||||||||||||||
| Non-GAAP income before income taxes |
$ |
65,284 |
|
$ |
40,529 |
|
$ |
195,661 |
|
$ |
156,988 |
|
||||||||||||||||||||||||
| GAAP benefit from (provision for) income taxes |
$ |
76,400 |
|
$ |
(80,805 |
) |
$ |
(356,462 |
) |
$ |
(359,763 |
) |
||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments (3) |
|
(93,040 |
) |
|
67,878 |
|
|
303,890 |
|
|
315,276 |
|
||||||||||||||||||||||||
| Non-GAAP provision for income taxes |
$ |
(16,640 |
) |
$ |
(12,927 |
) |
$ |
(52,572 |
) |
$ |
(44,487 |
) |
||||||||||||||||||||||||
| GAAP net (loss) income |
$ |
(258,816 |
) |
-46.2 |
% |
$ |
269,326 |
|
49.4 |
% |
$ |
1,205,189 |
|
71.4 |
% |
$ |
1,194,143 |
|
71.4 |
% |
||||||||||||||||
| Amortization of purchased intangibles |
|
5,809 |
|
|
6,529 |
|
|
16,490 |
|
|
20,179 |
|
||||||||||||||||||||||||
| Legal matters |
|
(1,900 |
) |
|
4,420 |
|
|
4,593 |
|
|
13,209 |
|
||||||||||||||||||||||||
| Acquisition related (benefits) costs (1) |
|
6 |
|
|
(2,756 |
) |
|
(7,762 |
) |
|
(2,862 |
) |
||||||||||||||||||||||||
| Restructuring (benefits) costs |
|
5,928 |
|
|
(10 |
) |
|
5,749 |
|
|
1,478 |
|
||||||||||||||||||||||||
| Valuation loss (gain) on equity-owned securities |
|
390,620 |
|
|
(318,007 |
) |
|
(1,384,999 |
) |
|
(1,420,339 |
) |
||||||||||||||||||||||||
| Loss (gain) on equity-method investments |
|
37 |
|
|
222 |
|
|
698 |
|
|
625 |
|
||||||||||||||||||||||||
| Other non-recurring items (2) |
|
– |
|
|
– |
|
|
(759 |
) |
|
(9,208 |
) |
||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments (3) |
|
(93,040 |
) |
|
67,878 |
|
|
303,890 |
|
|
315,276 |
|
||||||||||||||||||||||||
| Non-GAAP net income |
$ |
48,644 |
|
8.7 |
% |
$ |
27,602 |
|
5.1 |
% |
$ |
143,089 |
|
8.5 |
% |
$ |
112,501 |
|
6.7 |
% |
||||||||||||||||
| GAAP diluted (loss) income per share |
$ |
(8.68 |
) |
$ |
8.89 |
|
$ |
39.97 |
|
$ |
39.50 |
|
||||||||||||||||||||||||
| Amortization of purchased intangibles |
|
0.19 |
|
|
0.22 |
|
|
0.55 |
|
|
0.67 |
|
||||||||||||||||||||||||
| Legal matters |
|
(0.06 |
) |
|
0.15 |
|
|
0.15 |
|
|
0.44 |
|
||||||||||||||||||||||||
| Acquisition related (benefits) costs (1) |
|
– |
|
|
(0.09 |
) |
|
(0.26 |
) |
|
(0.09 |
) |
||||||||||||||||||||||||
| Restructuring (benefits) costs |
|
0.20 |
|
|
– |
|
|
0.19 |
|
|
0.05 |
|
||||||||||||||||||||||||
| Valuation loss (gain) on equity-owned securities |
|
12.94 |
|
|
(10.50 |
) |
|
(45.94 |
) |
|
(46.98 |
) |
||||||||||||||||||||||||
| Loss (gain) on equity-method investments |
|
– |
|
|
0.01 |
|
|
0.02 |
|
|
0.02 |
|
||||||||||||||||||||||||
| Other non-recurring items (2) |
|
– |
|
|
– |
|
|
(0.03 |
) |
|
(0.30 |
) |
||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments (3) |
|
(3.09 |
) |
|
2.23 |
|
|
10.10 |
|
|
10.41 |
|
||||||||||||||||||||||||
| Add back anti-dilutive shares |
|
0.11 |
|
|
– |
|
|
– |
|
|
– |
|
||||||||||||||||||||||||
| Non-GAAP diluted income per share |
$ |
1.61 |
|
$ |
0.91 |
|
$ |
4.75 |
|
$ |
3.72 |
|
||||||||||||||||||||||||
| GAAP diluted weighted average shares used in per share calculation |
|
29,831 |
|
|
30,292 |
|
|
30,149 |
|
|
30,234 |
|
||||||||||||||||||||||||
| Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive |
|
358 |
|
|
– |
|
|
– |
|
|
– |
|
||||||||||||||||||||||||
| Non-GAAP diluted weighted average shares used in per share calculation |
|
30,189 |
|
|
30,292 |
|
|
30,149 |
|
|
30,234 |
|
||||||||||||||||||||||||
Contacts
Investor Contact:
Bio-Rad Laboratories, Inc.
Ilan Daskal, Executive Vice President
& Chief Financial Officer
510-724-7000
[email protected]
Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
[email protected]